Type: Oral
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Genetics, Pregnancy, and Pediatrics: Advances in Venous Thromboembolism
Hematology Disease Topics & Pathways:
Research, epidemiology, Clinical Research
Methods: Critically ill children aged 0-21 years admitted or transferred into a pediatric intensive care unit (PICU) at 32 U.S. centers were randomly selected to be enrolled in the study. Participants with a HA-VTE at admission or cardiac surgery within 2 weeks of PICU admission/transfer were excluded. Participants were prospectively followed via chart review for the development of a HA-VTE throughout their hospitalization and up to 30 days post discharge. Twenty-one variables that had been evaluated in univariate analyses from the previously-reported ICU-RAM derivation study were again analyzed in the present prospective cohort via univariate logistic regression. Variables with P-value of <0.1 were included in a multivariable logistic regression model, with P-values of <0.05 considered significant. Missing values were not imputed and complete case analysis was utilized.
Results: From January 2020 to July 2022, 4,504 participants were enrolled and 93 developed a HA-VTE (2.1%). Complete data were available for 65 HA-VTE cases and 3056 controls without HA-VTE. Median age for HA-VTE participants was 5.2 years (interquartile range [IQR] 1.0-15.2) compared to 6.6 years (IQR 1.7-13.8) for those without HA-VTE; 55% and 53% of each group, respectively, were males. Among seven variables that met criteria for evaluation in the updated multivariable model, central venous catheter (odds ratio [OR] 4.2, 95% confidence interval [CI] 2.4-7.4), cancer (OR 3.1, 95% CI 1.4-6.7), immobility (OR 2.0, 95% CI 1.2-3.4, prior hospitalization (OR 2.0, 95% CI 1.1-3.5) and mechanical ventilation (OR 1.9, 95% CI 1.1-3.4) were each independently associated with HA-VTE risk (Table 1). The validation RAM had an area under the receiver operating characteristic curve of 0.81 (95% CI, 0.75–0.86) (Figure 1), compared to 0.78 (95% CI=0.73-0.84) for the previous model.
Conclusions: The present work represents the largest external validation study of a HA-VTE RAM to date in critically ill children. We identified five independent risk factors for HA-VTE for children admitted to a PICU. Two of these factors were identified in the derivation study RAM, while three (cancer, prior hospitalization, and mechanical ventilation) were newly identified via this validation study.
Disclosures: Jaffray: Hema Biologics: Consultancy; Behringer-Ingelheim: Other: Consortium lead to run their observational drug study; Daiichi Sankyo: Consultancy; Bayer: Consultancy; Genetech: Consultancy; Octapharma: Consultancy. Branchford: Kendrion: Other: Industry initiated study member; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Sana Biologics: Other: Contract Laboratory work. Faustino: Diagnostica Stago: Other: Equipment loan and reagents; Grifols: Research Funding. Young: Sanofi Genzyme: Consultancy, Speakers Bureau; Genentech/Roche: Consultancy; Hema Biologics: Speakers Bureau; Hema Biologics/LFB: Consultancy; CSL Behring: Consultancy, Speakers Bureau; Spark: Consultancy, Speakers Bureau; Takeda: Consultancy, Research Funding; Viatris: Patents & Royalties; Genentech, Inc.: Research Funding; Novo Nordisk: Consultancy. Goldenberg: Bayer: Consultancy; Boehringer-Ingelheim: Consultancy; Chiesi: Consultancy; Astra Zeneca: Consultancy; Daiichi Sankyo: Consultancy; University of Colorado-affiliated Academic Research Organization CPC Clinical Research: Other: Serves on clinical trials oversite committees for pharma studies; Novartis: Other: Data and Safety Monitoring Committee; Anthos Therapeutics: Consultancy.